Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
This phase II trial studies how well obinutuzumab and ibrutinib work as front line therapy in treating patients with indolent non-Hodgkin's lymphoma. Monoclonal antibodies, such as obinutuzumab, may interfere with the ability of cancer cells to grow and spread. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving obinutuzumab and ibrutinib may work better in treating patients with non-Hodgkin's lymphomas.
Full description
PRIMARY OBJECTIVES:
I. To assess the efficacy of the combination of ibrutinib and obinutuzumab in chemotherapy naive patients with indolent lymphomas.
SECONDARY OBJECTIVES:
I. To assess progression free survival rates and overall survival rates in indolent lymphomas.
II. To assess safety and tolerability of the combination. III. To evaluate response using positron emission tomography (PET) and correlate PET negativity with durability of response.
OUTLINE:
Patients receive ibrutinib orally (PO) once daily (QD) on days 1-28. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also receive obinutuzumab intravenously (IV) on days 1, 8, and 15 of cycle 1 and day 1 of subsequent cycles. Treatment repeats every 28 days for up to 6 cycles in the absence of disease progression or unacceptable toxicity. Beginning 2 months after cycle 6, patients with stable disease will continue to receive obinutuzumab every 2 months for a total of 12 doses.
After completion of study treatment, patients are followed up monthly for 1 year, every 3-6 months for 4 years, and then 1 year later.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Previously untreated, histologically confirmed indolent non-Hodgkin's lymphoma as follows:
Follicular lymphoma (World Health Organization [WHO] classification grade 1, 2, or 3a)
Marginal zone lymphoma including:
Nodal and splenic marginal zone lymphoma (MZL) who have an indication for systemic therapy
Extranodal MZL:
Pathological diagnosis should be obtained by incisional or excisional tissue biopsy; core biopsy is permissible if obtaining an incisional or excisional is not possible and if the grade can be assessed on the core biopsy; a core biopsy can also be used if deemed in the best interest of the patient in the opinion of the investigator
Patients must have stage II-IV disease
All patients should have measurable disease; measurable disease is defined as a lymph node or tumor mass that is >= 1.5 cm in at least one dimension by computed tomography (CT) or the CT portion of the PET/CT
Documentation of CD20+ status
Patients must have an indication for therapy per standard modified Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria including:
Age > 18 years
Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Patients must be able to swallow whole pills
Ability and willingness to comply with the requirements of the study protocol; when it is determined by the study investigator that a potential research participant is cognitively impaired, a surrogate consent from a caregiver or legally-authorized representative will be obtained. Caregiver or legally-authorized representative will ensure that they comply with the protocol in order for the subject to be considered eligible
Female subjects who are of non-reproductive potential (i.e., post-menopausal by history - no menses for >= 1 year; OR history of hysterectomy; OR history of bilateral tubal ligation; OR history of bilateral oophorectomy); female subjects of childbearing potential must have a negative urine/serum pregnancy test upon study entry
Male and female subjects who agree to use both a highly effective method of birth control (e.g., implants, injectables, combined oral contraceptives, some intrauterine devices [IUDs], complete abstinence , or sterilized partner) and a barrier method (e.g., condoms, vaginal ring, sponge, etc) during the period of therapy; female patients of reproductive potential who are not surgically sterile must practice adequate birth control for a minimum of twelve months post-treatment; male patients who are not surgically sterile must practice adequate birth control for a minimum of three months post-treatment
Absolute neutrophil count > 1.5 x 10^9 cells/mm^3
Platelet count > 50,000 cells/mm^3 (50 x 10^9/L)
Hemoglobin > 9.0 g/dL
Serum aspartate transaminase or alanine transaminase =< 3.0 x upper limit of normal (ULN)
Prothrombin time (PT)/international normalized ratio (INR) < 1.5 x ULN and activated partial thromboplastin time (aPTT) < 1.5 x ULN (unless abnormalities are unrelated to coagulopathy or bleeding disorder)
Estimated creatinine clearance >= 30 ml/min (calculated according using Cockcroft-Gault formula)
Bilirubin =< 1.5 x ULN (unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin)
Patients with Child Pugh B or C liver failure will be excluded
Exclusion criteria
Prior history of malignancies unless the patient has been disease free for >= 5 years; exceptions include basal cell carcinoma or squamous cell carcinoma of the skin; carcinoma in situ of cervix; carcinoma in situ of breast, localized prostate cancer, or superficial bladder cancer that has undergone curative therapy
Prior therapy for lymphoma including chemotherapy or immunotherapy including ibrutinib/anti-CD20 agents; patient may have received corticosteroids, but should be off them 2 weeks prior to study entry; known prior significant hypersensitivity to obinutuzumab (not including infusion reactions) or ibrutinib
Patients with evidence of large B cell transformation (transformed disease) are not eligible
Known central nervous system (CNS) involvement by lymphoma
Known bleeding disorders (e.g., von Willebrand's disease or hemophilia)
Concomitant use of warfarin or other vitamin K antagonists
Requires treatment with a strong cytochrome P450 (CYP) 3A inhibitor
Known active bacterial, viral, fungal, mycobacterial, or other infection (excluding fungal infections of nail beds) or any major episode of infection requiring treatment with IV antibiotics or hospitalization (related to the completion of the course of antibiotics) within 4 weeks before the start of cycle 1
Known infection with human immunodeficiency virus (HIV) or human T-cell leukemia virus 1 (HTLV-1) seropositive status
Viral hepatitis:
Vaccination with a live vaccine a minimum of 28 days prior to the start of treatment
Patient is receiving other investigational drugs
Prior chemotherapy for any other cancer within the last 2 years
Patients should not have active or uncontrolled autoimmune hemolytic anemia or immune thrombocytopenia
Patients should not have transfusion-dependent thrombocytopenia or bleeding disorders
Patients should not have an autoimmune disorder that requires active immunosuppression
Patients should not have a history of uncontrolled seizures
Currently active, clinically significant cardiovascular disease, such as uncontrolled arrhythmia or class 3 or 4 congestive heart failure as defined by the New York Heart Association functional classification; or a history of myocardial infarction, unstable angina, or acute coronary syndrome within 6 months prior to enrollment on the study
Patients should not have a stroke or intracranial hemorrhage within last 6 months
Prior surgery: patients may not have had major surgery within 28 days of enrollment, or minor surgery within 7 days of enrollment; examples of minor surgery include dental surgery, insertion of a venous access device, skin biopsy, or aspiration of a joint; the decision about whether a surgery is major or minor can be made at the discretion of the treating physician
Any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator's opinion, could compromise the subject's safety or put the study outcomes at undue risk
Pregnant and nursing: female patients must have a negative serum pregnancy test within 72 hours prior to initiating protocol therapy and be practicing an effective form of contraception during protocol therapy and for at least 4 weeks following completion of protocol therapy
Currently active, clinically significant hepatic impairment Child-Pugh class B or C according to the Child Pugh classification
Primary purpose
Allocation
Interventional model
Masking
30 participants in 1 patient group
Loading...
Central trial contact
Ubaldo Martinez-Outschoorn, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal